Chemotherapy (CT) followed by donor lymphocyte infusion (DLI) plus interleukin 2 (IL-2) for patients with relapse acute myeloid or lymphoid leukemia after allogeneic hematopoietic transplant.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Antineoplastics; Interleukin-2
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

02 Apr 2010 Biomarkers information updated
14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
11 Oct 2005 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com